Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,794.00
Bid: 6,778.00
Ask: 6,780.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.03%)
Open: 6,886.00
High: 6,919.00
Low: 6,736.00
Yest. Close: 6,880.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Barclays upgrades AstraZeneca on attractive growth outlook

(ShareCast News) - Barclays upgraded AstraZeneca to 'equalweight' from 'underweight' and lifted the price target to 5,000p from 4,400p following a review of the pipeline and the recent Acerta Pharma and ZS Pharma deals. It said the upgrade reflected "an attractive growth outlook balanced by the pote

19 Jan 16 08:55

LONDON BRIEFING: Market Accentuates The Positive In Weak Chinese Data

19 Jan 16 08:20

U.S. copy of GSK's Advair a step closer as Mylan files generic version

LONDON, Jan 12 (Reuters) - The arrival of cheap generic versions of GlaxoSmithKline's top-selling lung drug Advair has moved a step closer with confirmation from Mylan that it has submitted a generic version for approval. Mylan said late on Monday it had filed an abbreviated new drug appli

12 Jan 16 08:43

UPDATE 1-Novartis signs $170M immuno-oncology pact with Surface

(Adds details about $170 payment to Surface) By John Miller ZURICH, Jan 11 (Reuters) - Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body's immune system fight cancer. The accord, whi

11 Jan 16 18:15

AstraZeneca Announces Collaborations With Incyte, Moderna In Cancer

11 Jan 16 12:22

UPDATE 1-Sanofi deepens cancer drive with $1.2 bln of deals, Innate jumps

(Adds details on deals, Innate Pharma shares) PARIS, Jan 11 (Reuters) - Sanofi boosted its presence in cancer research on Monday by signing two deals with biotech companies worth up to $1.2 billion, as the French drugmaker plays catch-up with rivals in the hot research field. Shares i

11 Jan 16 08:27

BROKER RATINGS SUMMARY: Liberum Initiates Royal Mail With Sell Rating

7 Jan 16 09:34

BROKER RATINGS SUMMARY: S&P CapIQ Cuts Next To Buy From Strong Buy

5 Jan 16 09:43

HSBC lifts AstraZeneca target price on haematological cancer forecasts

(ShareCast News) - HSBC has hiked its target price for AstraZeneca shares after the pharmaceutical giant's acquisition of cancer specialist Acerta Pharma a week before Christmas. AstraZeneca revealed it had agreed to acquire a 55% stake in privately-owned Acerta for $2.5bn, with another $1.5bn due u

4 Jan 16 13:01

REPEAT: AstraZeneca's Zurampic Gets US Approval For Gout Patients

23 Dec 15 07:24

AstraZeneca gout treatment gets FDA approval

(ShareCast News) - AstraZeneca said its Zurampic drug, used to treat gout, had received approval from the US Food and Drug Adminstration. Zurampic, also known as Lesinurad, is used in combination with another type of drug that reduces production of uric acid in the body. Sean Bohen, Executive Vice

23 Dec 15 07:12

AstraZeneca's Zurampic Gets US Approval For Gout Patients

23 Dec 15 07:09

AstraZeneca gets U.S. approval for gout drug Zurampic

Dec 22 (Reuters) - U.S. health regulators on Tuesday approved AztraZeneca's drug Zurampic to treat a condition associated with gout to be used in combination with another type of drug that reduces production of uric acid in the body. Zurampic, known chemically as lesinurad, works by helping

22 Dec 15 23:16

AstraZeneca Gets Spate Of Positive Opinions From EU Committee

18 Dec 15 13:03

New drug trial data supports AstraZeneca's clinical activity

(ShareCast News) - AstraZeneca said on Friday that preliminary findings from the ATLANTIC trial of durvalumab, a treatment for a type of non-small cell lung cancer, supports the treatment's clinical activity. The FTSE 100 company said the treatment demonstrated clinical activity and durable response

18 Dec 15 07:52

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.